Form 4: Seres Therapeutics Executive VP Sells Shares to Cover Taxes After RSU Vesting

Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, sold 3,338 shares of common stock at an average price of $0.8102 to cover taxes related to the vesting of restricted stock units.

Summary

• On February 15, 2025, Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, had 2,657 and 7,813 Restricted Stock Units vest.
• Following the vesting of these units, Ms. Young sold 3,338 shares of common stock on February 18, 2025, at a weighted average price of $0.8102 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2023, to cover tax obligations associated with the vesting of the restricted stock units.
• After the reported transactions, Ms. Young directly owns 97,536 shares of Seres Therapeutics common stock.
• Ms. Young also holds 21,250 and 23,437 Restricted Stock Units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine stock sale by an executive to cover tax obligations. It doesn't indicate any fundamental change in the company's prospects.

Industry Context

Sales by company executives are a normal part of equity compensation and are often planned in advance to comply with insider trading regulations. The use of a 10b5-1 plan is a common practice to avoid any appearance of trading on inside information.

Stakeholder Impact

• The stock sale may have a minor, temporary impact on the stock price due to the increased selling pressure.
• The sale does not appear to have any significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Seres Therapeutics, MCRB, Teresa L. Young, Stock Sale, Restricted Stock Units, Rule 10b5-1, Executive Compensation, Insider Trading